New drug cocktail aims to wipe out Hard-to-Treat leukemia and MDS
NCT ID NCT07153497
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding olutasidenib to standard treatments helps people with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). For AML, the standard is a chemotherapy pill plus venetoclax; for higher-risk MDS, it's the chemotherapy pill alone. The study will enroll 132 people and measure how many achieve complete remission or improved blood counts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olutasidenib (a targeted drug that blocks the mutated IDH1 protein), decitabine-cedazuridine (ASTX727, a chemotherapy pill), and venetoclax (a targeted drug that helps kill cancer cells)
What this could lead to
If successful, this combination could become a new standard treatment for people with IDH1-mutant AML or MDS, leading to higher remission rates and better blood counts.
What could go wrong
This is a phase 2 trial, so it is still early. The added drug may not improve outcomes enough, or side effects could outweigh benefits. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.